ArticleJournal of clinical and experimental hematopathology : JCEH2022

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.

Ai Omi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.